ArticleNutrients2019
Safety of Hyaluronan 35 in Healthy Human Subjects: A Pilot Study.
Open access · goldAbstract read
In one paragraph
Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Hyaluronan 35 prevents endotoxin-mediated dysregulated skeletal muscle proteostasis during ethanol exposure.American journal of physiology. Endocrinology and metabolism · 2026Article
- Supramolecular Co-Assembled Fmoc-FRGDF/Hyaluronic Acid Hydrogel for Quercetin Delivery: Multifunctional Bioactive Platform.Foods (Basel, Switzerland) · 2025Article
- Application of 35 kDa Hyaluronic Acid Fragment in Managing Persistent Localized Pain in Rheumatoid Arthritis : A Case Report.Clinical case reports · 2025Article
- 35k Da specific-sized hyaluronan ameliorates high-fat diet-induced liver injury in murine model of moderate obesity.Matrix biology : journal of the International Society for Matrix Biology · 2025Article
- Size-dependent aggregation of erythrocytes by low molecular weight hyaluronic acids of different sizes: bioactivity and quality control potential.Frontiers in physiology · 2025Article
- Hyperglycemic environments directly compromise intestinal epithelial barrier function in an organoid model and hyaluronan (∼35 kDa) protects via a layilin dependent mechanism.Matrix biology : journal of the International Society for Matrix Biology · 2024Article
- A clinical study of the local injection of a freshly manufactured 35 kDa hyaluronan fragment for treating chronic wounds.International wound journal · 2024Article
- Characterization, Bioactivity, and Biodistribution of 35 kDa Hyaluronan Fragment.Life (Basel, Switzerland) · 2024Article
- Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models.Frontiers in pharmacology · 2024Review
- Electrospun Food Polysaccharides Loaded with Bioactive Compounds: Fabrication, Release, and Applications.Polymers · 2023Review
- [Preparation and bone repair capability of a new plastic bone filler material].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2023Article
- 35kDa hyaluronan ameliorates ethanol driven loss of anti-microbial defense and intestinal barrier integrity in a TLR4-dependent manner.Matrix biology : journal of the International Society for Matrix Biology · 2023Article
- Modulation of hyaluronan signaling as a therapeutic target in human disease.Pharmacology & therapeutics · 2022Review
- The Role of Hyaluronan Treatment in Intestinal Innate Host Defense.Frontiers in immunology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Annette BellarDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. bellara@ccf.org.
Sean P KesslerDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. kessles@ccf.org.
Dana R OberyDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. oberyd@ccf.org.
Naseer SangwanCenter for Microbiome and Human Health, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. sangwan@ccf.org.
Nicole WelchDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. welchn@ccf.org.
Laura E NagyDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. nagyl3@ccf.org.
Srinivasan DasarathyDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. dasaras@ccf.org.ORCID 0000-0003-1774-0104
Carol de la MotteDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. delamoc@ccf.org.
Cleveland Clinic Lerner College of Medicine · US
Funding
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5MProject Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Thomas M McIntyre · 2016 to 2026
$19.6MVERSICAN PROTEOLYSIS AND REGULATION OF VASCULAR SMOOTH MUSCLEP01HL107147 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI LAUER, MARK E · 2011 to 2017
$16.1MNon Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2MSarcopenia in cirrhosis is mediated by a hyperammonemic stress responseR01DK113196 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, HATZOGLOU, MARIA · 2018 to 2021
$2.3MSpecific-sized hyaluronan: a dual targeted therapy for ALDR01AA026764 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2018 to 2022
$2.1MMechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01GM119174 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2017 to 2020
$1.2MNCATS NIH HHS UL1 TR002548NHLBI NIH HHS P01 HL107147NIAAA NIH HHS P50 AA024333NIAAA NIH HHS R01 AA026764NIDDK NIH HHS R01 DK113196NIDDK NIH HHS U01 DK061732NIGMS NIH HHS R01 GM119174NIH HHS R21 AA022742; RO1 DK 113196; RO1 GM119174; P50 AA024333; UO1 AA021890, UO1 AA026975; UO1 DK061732 P01 HL107417-S1 R01 AA026764
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAnti-Inflammatory Agentsbeta-DefensinsDigestive System DiseasesEnergy MetabolismFecesFemaleHumansHyaluronic AcidLeukocyte L1 Antigen ComplexMaleMicrobiotaMolecular WeightPilot ProjectsProspective StudiesAnti-Inflammatory Agentsbeta-DefensinsDEFB4A protein, humanHyaluronic AcidLeukocyte L1 Antigen Complexanti-inflammatoryclinical trialhumanhyaluronanmicrobiome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.